Advances in Narcolepsy

Medical Clinics of North America

Volumn 94, Issue 3, 2010, Pages 541-555

  Cao, Michelle ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cataplexy; Excessive daytime sleepiness; Hypocretin; Modafinil; Narcolepsy; Sodium oxybate

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; ARMODAFINIL; ATOMOXETINE; BACLOFEN; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; HLA DQB1 ANTIGEN; HLA DR2 ANTIGEN; IMIPRAMINE; IMMUNOGLOBULIN; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OREXIN 2 RECEPTOR; OREXIN A; OXYBATE SODIUM; PLACEBO; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BEDTIME DOSAGE; BEHAVIOR THERAPY; CATAPLEXY; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DISORIENTATION; DIZZINESS; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENURESIS; HUMAN; HYPNAGOGIC HALLUCINATION; INSOMNIA; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROTRANSMISSION; NIGHT SLEEP; NONHUMAN; PARASOMNIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REM SLEEP; REVIEW; SIDE EFFECT; SKIN TEMPERATURE; SLEEP; SLEEP WAKING CYCLE; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES;

EID: 77951683588     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.02.008     Document Type: Review

References (99)

1. Mignot E., Wang C., Rattazzi C., et al. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci U S A 88 (1991) 3475-3478
2. American Academy of Sleep Medicine. International classification of sleep disorders: diagnostic and coding manual. 2nd edition (2005), American Academy of Sleep Medicine, Westchester (IL)
3. Roth B. Narcolepsy and hypersomnia (1980), Karger, Basel (Switzerland)
4. Honda Y. Clinical features of narcolepsy. In: Honda Y., and Juji T. (Eds). HLA in narcolepsy (1988), Springer-Verlag, Berlin 24-57
5. Brooks S., and Mignot E. Narcolepsy and idiopathic hypersomnia. In: Lee-Chiong T., Sateia M., and Carskadon M. (Eds). Sleep medicine (2002), Hanley & Belfus, Inc, Philadelphia 193-202
6. Bassetti C., and Aldrich M.S. Narcolepsy. Neurol Clin 14 3 (1996) 545-571
7. Nishino S., Okuro M., Kotorii N., et al. Hypocretin/orexin and narcolepsy: new basic and clinical insights. Acta Physiol (Oxf) 198 (2010) 209-222
8. Juji T., Satake M., Honda Y., et al. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24 (1984) 316-319
9. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 (1997) 27-78
10. Mignot E., Hayduk R., Grumet F.C., et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20 (1997) 1012-1020
11. de Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamic-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1998) 322-327
12. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
13. Peyron C., Tighe D.K., van den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
14. Lin L., Faraco R., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
15. Chemelli R.M., Willie J.T., Sinton C.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
16. Hara J., Beuckmann C.T., Nambu T., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
17. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
18. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 (2007) 499-511
19. Thannickal T., Moore R., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
20. Honda M., Erikson K.S., Zhang S., et al. IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One 4 (2009) e4254
21. Blouin A.M., Thannickal T.C., Worley P.F., et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65 (2005) 1189-1192
22. Crocker A., Espana R.A., Papadopoulou M., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 (2005) 1184-1188
23. Black III J.L., Krahn L.E., Pankratz V.S., et al. Search for neuron-specific and non-neuron specific antibodies in narcoleptic patients with an without HLA DQB1*0602. Sleep 25 (2002) 719-723
24. Black III J.L., Silber M.H., Krahn L.E., et al. Studies of humoral immunity to pre-prohypocretin in human leukocyte antigen DQB1*0602 positive narcoleptic subjects with cataplexy. Biol Psychiatry 58 (2005) 504-509
25. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 (1998) S16-S22
26. Hohjoh H., Nakayama T., Ohashi J., et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 54 (1999) 138-145
27. Park M.H., Roh E.Y., Park H., et al. Association of TNF-alpha gene promoter polymorphism with narcolepsy-cataplexy in Koreans. Hum Immunol 65 (2004) S110
28. Kawashima M., Tamiya G., Oka A., et al. Genome wide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 79 (2006) 252-263
29. Miyagawa T., Kawashima M., Nishida N., et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 40 (2008) 1324-1328
30. Hohjoh H., Terada N., Kawashima M., et al. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 56 (2000) 446-448
31. Hallmayer J., Faraco J., Lin L., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41 (2009) 708-711
32. De Lecea L. A decade of hypocretins: past, present, and future of the neurobiology of arousal. Acta Physiol (Oxf) 198 (2010) 203-208
33. Kroeger D., and de Lecea L. The hypocretins and their role in narcolepsy. CNS Neurol Disord Drug Targets 8 (2009) 271-280
34. Horvath T.L., Diano S., and van den Pol A.N. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci 19 (1999) 1072-1087
35. Guan J.L., Wang Q.P., and Shioda S. Immunoelectron microscopic examination of orexin-like immunoreactive fibers in the dorsal horn of the rat spinal cord. Brain Res 987 (2003) 86-92
36. Van den Pol A.N. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19 (1999) 3171-3182
37. Cutler D.J., Morris R., Sheridhar V., et al. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 20 (1999) 1455-1470
38. Aston-Jones G., Smith R.J., Moorman D.E., et al. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56 (2009) 112-121
39. Harris G.C., Wimmer M., and Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437 (2005) 556-559
40. Rodgers R.J., Halford J.C.G., Nunes de Souza R.L., et al. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioral satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13 (2001) 1444-1452
41. Rodgers R.J., Ishii Y., Halford J.C.G., et al. Orexins and appetite regulation. Neuropeptides 36 (2002) 303-325
42. Haynes A.C., Jackson B., Chapman H., et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 96 (2000) 45-51
43. Lin Y., Matsumura K., Tsuchihashi T., et al. Chronic central infusion of orexin-A increases arterial pressure in rats. Brain Res Bull 57 (2002) 619-622
44. Haynes A.C., Jackson B., Overend P., et al. Effects of single and chronic intracerebroventricular administration of orexins on feeding in the rat. Peptides 20 (1999) 1099-1105
45. Yamanaka A., Sakurai T., Katsumoto T., et al. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849 (1999) 248-252
46. Nambu T., Sakurai T., Mizukami K., et al. Distribution of orexin neurons in the adult rat brain. Brain Res 827 (1999) 243-260
47. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8 (2007) 171-181
48. Funato H., Tsai A.L., Willie J.T., et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 9 (2009) 64-76
49. Narita M., Nagumo Y., Hashimoto S., et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26 (2006) 398-405
50. Georgescu D., Zachariou V., Barrot M., et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23 (2003) 3106-3111
51. Bernardis L.L., Awad A., Fink C., et al. Metabolic and neuroendocrine indices one month after lateral hypothalamic area lesions. Physiol Behav 52 (1992) 133-139
52. Stern J.E. Electrophysiological and morphological properties of pre-autonomic neurons in the rat hypothalamic paraventricular nucleus. J Physiol 537 (2001) 161-177
53. Kuru M., Ueta Y., Serino R., et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 11 (2000) 1977-1980
54. Sakamoto F., Yamada S., and Ueta Y. Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central orexins on stress-activated central CRF neurons. Regul Pept 118 (2004) 183-191
55. Shirasaka T., Nakazato M., Matsukura S., et al. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol Regul Integr Comp Physiol 277 (1999) R1780-R1785
56. Mochizuki T., Klerman E.B., Sakurai T., et al. Elevated body temperature during sleep in orexin knock out mice. Am J Physiol Regul Integr Comp Physiol 1 3 (2006) R533-R540
57. Han F, Mignot E, Wei YC, et al. Ventilatory chemoresponsiveness, narcolepsy-cataplexy, and HLA DQB1*0602 staus. Eur Respir J 2010, in press.
58. Moscovitch A., Partinen M., and Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 43 (1993) 55-60
59. Aldrich M.S. The neurobiology of narcolepsy-cataplexy. Prog Neurobiol 41 (1993) 533-541
60. Dauvilliers Y., Gosselin A., Paquet J., et al. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 62 (2004) 46-50
61. Singh M., Drake C.L., and Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 29 7 (2006) 890-895
62. In: Honda Y., and Juji T. (Eds). HLA in narcolepsy (1988), Springer-Verlag, Berlin 10-57
63. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 35 5 (2000) 39-40
64. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
65. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9 (2005) 269-310
66. Kanbayashi T., Shimohata T., Nakashima I., et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 66 (2009) 1563-1566
67. Lammers G.J., Arends J., Declerk A.C., et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16 (1993) 216-220
68. U.S. Xyrem Multicenter Study Group. A randomized, double blind, multicenter trial comparing the effect of 3 doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25 (2002) 42-49
69. Borgen L.A., Okerholm R.A., Lai A., et al. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 44 (2004) 253-257
70. Huang Y.S., and Guilleminault C. Narcolepsy: action of two γ-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 41 (2009) 9-16
71. Bensmail D., Quera Salva M.A., Roche N., et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 67 (2006) 1432-1436
72. Scharf M.B., Brown D., Woods M., et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychol 46 (1985) 222-225
73. Black J., Pardi D., Hornfeldt C.S., et al. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 10 8 (2009) 829-835
74. Wisor J., Nishino S., Sora I., et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21 5 (2001) 1787-1794
75. Mignot E., Nishino S., Guilleminault C., et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 15 5 (1994) 436-437
76. Black J., and Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29 7 (2006) 939-946
77. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 4 3 (2008) 557-566
78. Lankford D.A. Armodafinil: a new treatment for excessive sleepiness. Expert Opin Investig Drugs 17 (2008) 565-573
79. Harsh J.R., Hayduk R., Rosenberg R., et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22 (2006) 761-774
80. Garmock-Jones K.P., Dhillon S., and Scott L.J. Armodafinil. CNS Drugs 23 9 (2009) 793-803
81. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 8 (2007) 427-440
82. Mieda M., Willie J.T., Hara J., et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 101 (2004) 4649-4654
83. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 8 (2007) 373-399
84. Hanson L.R., Martinez P.M., Taheri S., et al. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Delivery Technol 4 (2004) 66-71
85. Deadwyler S.A., Porrino L., Siegel J.M., et al. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27 (2007) 14239-14247
86. Lecendreux M., Maret S., Bassetti C., et al. Clinical efficacy of high-dose intravenous immunoglobins near the onset of narcolepsy in a 10-year old boy. J Sleep Res 12 4 (2003) 347-348
87. Zuberi S.M., Mignot E., Ling L., et al. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 13 Suppl 1 (2004) 828
88. Dauvilliers Y., Carlander B., Rivier F., et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56 6 (2004) 905-908
89. Gemkow M.J., Davenport A.J., Harich S., et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 14 (2009) 509-515
90. Nishino S., Arrigoni J., Shelton J., et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 17 (1997) 6401-6408
91. Le S., Gruner J.A., Mathiasen J.R., et al. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 325 (2008) 902-909
92. Parmentier R., Anaclet C., Guhennec C., et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 73 (2007) 1157-1171
93. Barbier A.J., Berridge C., Dugovic C., et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143 5 (2004) 649-661
94. Shiba T., Fujiki N., Wisor J.P., et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 27 Abstract Suppl (2004) S241-S242
95. Leurs R., Bakker R.A., Timmerman H., et al. The histamine H-3 receptor: from gene cloning to H-3 receptor drugs. Nat Rev Drug Discov 4 2 (2005) 107-120
96. Lin J.S., Dauvilliers Y., Arnulf I., et al. An inverse agonist of the histamine H-3 receptor improves wakefulness in narcolepsy: studies in orexin(-/-) mice and patients. Neurobiol Dis 30 1 (2008) 74-83
97. Fronczek R., Overeem S., Lammers G.J., et al. Altered skin-temperature regulation in narcolepsy relates to sleep propensity. Sleep 11 (2006) 1444-1449
98. Krauchi K., Cajochen C., Werth E., et al. Warm feet promote the rapid onset of sleep. Nature 6748 (1999) 36-37
99. Fronczek R., Raymann R., Romeijn N., et al. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep 31 2 (2008) 233-240